01 4Biktarvy
02 5Descovy
03 5Genvoya
04 5Odefsey
05 2Revenue share - Symtuza
06 3Symtuza
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 3,338
2019 Revenue in Millions : 3,931
Growth (%) : -15
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 488
2019 Revenue in Millions : 379
Growth (%) : 29
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 1,861
2019 Revenue in Millions : 1,500
Growth (%) : 24
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 1,672
2019 Revenue in Millions : 1,655
Growth (%) : 1
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 7,259
2019 Revenue in Millions : 4,738
Growth (%) : 53
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 531
2020 Revenue in Millions : 488
Growth (%) : 9
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 1,568
2020 Revenue in Millions : 1,672
Growth (%) : -6
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 2,879
2020 Revenue in Millions : 3,338
Growth (%) : -14
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 1,700
2020 Revenue in Millions : 1,861
Growth (%) : -9
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 530
2021 Revenue in Millions : 531
Growth (%) : 0
LOOKING FOR A SUPPLIER?